Supernus Pharmaceuticals, Inc. $SUPN Shares Purchased by Bank of America Corp DE

Key Points

• Bank of America increased its Supernus Pharmaceuticals stake by 37.2% in the first quarter, acquiring 193,479 additional shares for a total of 714,226 shares valued at approximately $36.9 million.
• Supernus shares opened at $48.27, with a market capitalization of about $2.81 billion. The stock has traded between $41.78 and $59.68 over the past year.
• Analyst sentiment is generally positive, with a consensus rating of “Moderate Buy” and an average price target of $62.83, although ratings range from Strong Buy to Sell.

Bank of America Corp DE lifted its stake in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Free Report) by 37.2% during the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 714,226 shares of the specialty pharmaceutical company's stock after purchasing an additional 193,479 shares during the quarter. Bank of America Corp DE owned about 1.23% of Supernus Pharmaceuticals worth $36,918,000 at the end of the most recent quarter.

Other large investors have also made changes to their positions in the company. Rockefeller Capital Management L.P. increased its holdings in Supernus Pharmaceuticals by 354.8% during the 4th quarter. Rockefeller Capital Management L.P. now owns 846 shares of the specialty pharmaceutical company's stock valued at $42,000 after acquiring an additional 660 shares in the last quarter. Torren Management LLC acquired a new position in shares of Supernus Pharmaceuticals during the 4th quarter valued at about $49,000. EverSource Wealth Advisors LLC purchased a new position in shares of Supernus Pharmaceuticals during the 2nd quarter worth about $51,000. Hantz Financial Services Inc. lifted its holdings in shares of Supernus Pharmaceuticals by 73.3% during the 4th quarter. Hantz Financial Services Inc. now owns 1,083 shares of the specialty pharmaceutical company's stock worth $54,000 after acquiring an additional 458 shares during the period. Finally, Raymond James Financial Inc. acquired a new position in shares of Supernus Pharmaceuticals in the 2nd quarter valued at $55,000.

Supernus Pharmaceuticals Price Performance

SUPN opened at $48.27 on Friday. The stock has a market capitalization of $2.81 billion, a PE ratio of -25.14, a P/E/G ratio of 0.87 and a beta of 0.56. The firm's fifty day moving average price is $46.46 and its 200 day moving average price is $48.86. Supernus Pharmaceuticals, Inc. has a 12-month low of $41.78 and a 12-month high of $59.68.

Analyst Ratings Changes

A number of brokerages recently weighed in on SUPN. Zacks Research upgraded Supernus Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a report on Thursday, August 6th. Weiss Ratings restated a "sell (d+)" rating on shares of Supernus Pharmaceuticals in a report on Wednesday, June 24th. Cantor Fitzgerald boosted their target price on Supernus Pharmaceuticals from $63.00 to $67.00 and gave the stock an "overweight" rating in a report on Thursday, July 9th. Finally, Wall Street Zen downgraded shares of Supernus Pharmaceuticals from a "buy" rating to a "hold" rating in a research note on Saturday, August 8th. One analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Supernus Pharmaceuticals has an average rating of "Moderate Buy" and a consensus price target of $62.83.

Supernus Pharmaceuticals Profile

Supernus Pharmaceuticals, Inc, headquartered in Rockville, Maryland, is a specialty pharmaceutical company dedicated to developing and commercializing central nervous system (CNS) therapies. Since its founding in 2003, Supernus has focused on advancing treatments for neurological disorders, with an emphasis on improving patient quality of life through innovative dosage forms and sustained‐release formulations.

The company's marketed portfolio includes Trokendi XR and Oxtellar XR, extended‐release antiepileptic medications designed to maintain stable drug levels for seizure control, as well as Qelbree (viloxazine extended‐release capsules), approved for the treatment of attention‐deficit/hyperactivity disorder (ADHD) in pediatric and adult patients.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source